Loading…
Reliance Pharma Fund
Disclosed for 84 months, Sep 2012 to Aug 2019. This scheme is no longer reporting.Published as: RELIANCE PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹1,616 Cr
up ₹50.3 Cr vs Sep 2016
- Stocks held
- 17
Reliance Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In October 2016 it disclosed 17 stocks worth ₹1,616 Cr, up ₹50.3 Cr from Sep 2016. Its largest positions were Abbott India Limited (10.7%), Lupin Limited (9.4%), Sanofi India Limited (8.5%); the ten largest together made up 78.4% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 82.3% of its equity. Cash and debt stood at 1.2%. Compared with Sep 2016 the fund entered 1 new stock and exited 0.
Against 227 other Sectoral / Thematic funds
Concentration
98%
Top-10 weight is higher than 98% of peers
Breadth
4%
Holds more stocks than 4% of peers
Cash
15%
Holds more cash than 15% of peers
What these mean: concentration · cash
Holdings in October 2016
Download CSVEvery line the fund disclosed, with the change against Sep 2016. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Abbott India Limited | 10.72% | up 0.22 pts | ₹173 Cr | up ₹8.8 Cr | Added |
| Lupin Limited | 9.44% | up 1.61 pts | ₹153 Cr | up ₹29.9 Cr | Added |
| Sanofi India Limited | 8.53% | up 0.18 pts | ₹138 Cr | up ₹7.1 Cr | Added |
| Zydus Lifesciences Limited | 8.12% | up 0.44 pts | ₹131 Cr | up ₹10.9 Cr | Added |
| Aurobindo Pharma Limited | 7.62% | down 0.67 pts | ₹123 Cr | down ₹6.6 Cr | Trimmed |
| Divi's Laboratories Limited | 7.53% | down 1.13 pts | ₹122 Cr | down ₹13.8 Cr | Trimmed |
| Cipla Limited | 7.48% | down 1.05 pts | ₹121 Cr | down ₹12.6 Cr | Trimmed |
| Sun Pharmaceutical Industries Limited | 6.90% | down 0.21 pts | ₹112 Cr | up ₹11 L | Held |
| Dr. Reddy's Laboratories Limited | 6.26% | up 0.29 pts | ₹101 Cr | up ₹7.7 Cr | Added |
| Thyrocare Technologies Limited | 5.82% | up 0.07 pts | ₹94.1 Cr | up ₹4.1 Cr | Added |
| Healthcare Global Enterprises Limited | 5.71% | up 0.39 pts | ₹92.3 Cr | up ₹9 Cr | Added |
| IPCA Laboratories Limited | 4.61% | down 0.37 pts | ₹74.5 Cr | down ₹3.5 Cr | Trimmed |
| Max India Limited | 3.51% | up 1.73 pts | ₹56.7 Cr | up ₹28.9 Cr | Added |
| Glenmark Pharmaceuticals Limited | 2.31% | up 2.31 pts | ₹37.3 Cr | up ₹37.3 Cr | New |
| Biocon Limited | 1.72% | down 1.86 pts | ₹27.8 Cr | down ₹28.2 Cr | Trimmed |
| Indoco Remedies Limited | 1.49% | down 0.21 pts | ₹24.1 Cr | down ₹2.5 Cr | Trimmed |
| Cash, TREPS & receivables | 1.22% | down 1.69 pts | ₹19.7 Cr | down ₹25.8 Cr | Trimmed |
| Narayana Hrudayalaya Limited | 0.98% | down 0.07 pts | ₹15.8 Cr | down ₹54 L | Trimmed |
What changed, Sep 2016 to Oct 2016
New New positions (1)
- Glenmark Pharmaceuticals Limited2.3% · ₹37.3 Cr
Exited Exited (0)
None.
Added Biggest additions
- Lupin Limitedup ₹29.9 Cr (+1.61% pts)
- Max India Limitedup ₹28.9 Cr (+1.73% pts)
- Zydus Lifesciences Limitedup ₹10.9 Cr (+0.44% pts)
- Healthcare Global Enterprises Limitedup ₹9 Cr (+0.39% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Sep 2016, the weight rose most in Healthcare Services (+1.9 pts), and fell most in Pharmaceuticals & Biotechnology (−1.7 pts) and Pharmaceuticals (−0.2 pts).
- Healthcare Services14.3% → 16.2%+1.9 pts
- Pharmaceuticals & Biotechnology83.9% → 82.3%−1.7 pts
- Pharmaceuticals1.8% → 1.5%−0.2 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Oct 2013 | Oct 2015 | Apr 2016 | Jul 2016 | Sep 2016 | Oct 2016 |
|---|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 84.9% | 96.0% | 96.5% | 89.4% | 83.9% | 82.3% |
| Healthcare Services | 1.7% | 1.7% | 1.8% | 8.9% | 14.3% | 16.2% |
| Pharmaceuticals | 8.6% | 2.3% | 1.6% | 1.8% | 1.8% | 1.5% |
Allocation in Oct 2016change vs Sep 2016
- Pharmaceuticals & Biotechnology (12)82.3%▼ 1.7 pts
- Healthcare Services (4)16.2%▲ 1.9 pts
- Pharmaceuticals (1)1.5%▼ 0.2 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Oct 2016
1.2%
▼ 1.7 pts vs Sep 2016
- Cash alone
- 1.3%
- cash and net receivables
- A year earlier
- 2.9%
- Oct 2015 · now ▼ 1.7 pts
- Last 12 months
- 0.6% – 9.6%
- lowest to highest · record 9.6% in Nov 2015
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.